AstraZeneca lifts lid on data to be presented at ESMO this year

31 August 2017

At next week’s European Society of Medical Oncology (ESMO) Congress in Madrid, Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) and the company’s biologics arm MedImmune will make around 40 presentations, it has been revealed.

The data will include two pivotal readouts selected for late-breaking abstract presentation at the Presidential Symposia, which the company says demonstrate significant improvements over current standard-of-care treatments in lung cancer.

The presentations will include results from the Phase III PACIFIC trial showing statistically-significant progression-free survival (PFS) benefit for Imfinzi (durvalumab) as a second-line therapy in non-small cell lung cancer (NSCLC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK